Skip to Main Content
Bora Pharmaceuticals Completes the Acquisition of Upsher-Smith

Upsher-Smith Launches Doxazosin Tablets, USP

Maple Grove, MN – May 1, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Doxazosin Tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg. The product was approved by the U.S. Food and Drug Administration (FDA) on April 17, 2018. Upsher- Smith’s Doxazosin Tablets are an AB-rated generic version of the branded product, Cardura® (doxazosin mesylate tablets).*

The doxazosin tablet market had U.S. sales of approximately $51.2 million for the 12 months ending January, 2018 according to IQVIA.

Product Information

Product Active Ingredient Strength NDC # Package Size
Doxazosin Tablets, USP Doxazosin mesylate 1 mg 0832-0356-11 100 ct bottle
Doxazosin Tablets, USP Doxazosin mesylate 2 mg 0832-0357-11 100 ct bottle
Doxazosin Tablets, USP Doxazosin mesylate 4 mg 0832-0359-11 100 ct bottle
Doxazosin Tablets, USP Doxazosin mesylate 8 mg 0832-0358-11 100 ct bottle

 For questions about ordering, please call Upsher-Smith at 1-800-654-2299.

Please refer to the full Prescribing Information for Doxazosin Tablets, USP at You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.

You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting

About Upsher-Smith

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that has strived to deliver quality, affordable generic medications for nearly a century. In June 2017,

Upsher-Smith was acquired by Sawai Pharmaceutical Co., Ltd., a large publicly traded generics company in Japan that had been seeking entry into the U.S. market. Upsher-Smith and Sawai share a strikingly similar family history and hold many of the same cherished goals and values— most importantly, the philosophy of always putting patients first. Upsher-Smith will continue to do those things it does best, which is provide a consistent supply of quality, affordable medications and invest in its historically strong industry relationships. Ultimately, Upsher-Smith believes the acquisition by Sawai represents a tremendous opportunity to leverage each company for growth worldwide and embark together on an exciting new chapter in generics. For more information, visit

* Cardura is a registered trademark of Pfizer Inc.

Elizabeth Likly
Kovak-Likly Communications

Download Press Release


Join Our Team!

We’re hiring

Search Our Jobs